ArticleCellular and molecular life sciences : CMLS2026
Cartilage intermediate layer protein inhibits ligamentum flavum hypertrophy mediated by TGF-β1/SMAD3/SERPINE2 signaling pathway.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lumbar Spinal Stenosis (LSS), a degenerative disorder, greatly impacts the elderly, often leads to discomfort, neurological problems, and a diminished quality of life. Ligamentum flavum hypertrophy (LFH), a marked influencor in LSS, is characterized by fibrosis resulting from excessive extracellular matrix deposition, largely driven by the differentiation of fibroblasts and inflammatory processes. Transforming growth factor β1 (TGF-β1) is pivotal in the LFH advancement by promoting fibrosis, highlighting its potential as a target for therapeutic strategies. Cartilage intermediate layer protein (CILP), known to regulate TGF-β1 activity in other tissues, may have potential in mitigating LFH. This research explores the function of CILP in LFH through the use of sophisticated bioinformatics, human samples, and experimental models, identifying its regulatory influence via the TGF-β1/SMAD3/SERPINE2 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.